Nektar Therapeutics
NKTR
$0.8968
$0.08149.98%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -0.08% | 14.59% | 0.21% | 8.45% | 2.20% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.08% | 14.59% | 0.21% | 8.45% | 2.20% |
| Cost of Revenue | -64.32% | 39.26% | 20.88% | 16.85% | 150.02% |
| Gross Profit | 68.10% | 1.81% | -9.83% | 5.14% | -37.21% |
| SG&A Expenses | -10.36% | 14.78% | -4.42% | -21.05% | -6.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.34% | 9.96% | -4.30% | -13.30% | -5.64% |
| Operating Income | -2.37% | -7.17% | 6.93% | 25.02% | 10.59% |
| Income Before Tax | 19.28% | -2.24% | 73.13% | 25.53% | 22.47% |
| Income Tax Expenses | 114.75% | 197.87% | 44.44% | -100.92% | 60.65% |
| Earnings from Continuing Operations | 19.15% | -2.43% | 73.14% | 29.50% | 22.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 19.15% | -2.43% | 73.14% | 29.50% | 22.37% |
| EBIT | -2.37% | -7.17% | 6.93% | 25.02% | 10.59% |
| EBITDA | -4.71% | -9.87% | 5.38% | 23.07% | 8.58% |
| EPS Basic | 26.42% | 7.01% | 73.95% | 30.53% | 23.51% |
| Normalized Basic EPS | 2.56% | -2.37% | 11.67% | 25.12% | 19.63% |
| EPS Diluted | 26.42% | 7.01% | 73.95% | 31.07% | 23.51% |
| Normalized Diluted EPS | 2.56% | -2.37% | 11.67% | 25.12% | 19.63% |
| Average Basic Shares Outstanding | 9.90% | 10.11% | 3.11% | 1.49% | 1.47% |
| Average Diluted Shares Outstanding | 9.90% | 10.11% | 3.11% | 1.49% | 1.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
